 Don’t miss our top 5 cancer-related stories this month,
including a guest commentary from an industry leader, our two-part series on
trends in cancer research and more!
By E. Kevin Hrusovsky, PerkinElmer Inc. As the complexity and volume of data continue to rise, bioinformatics is emerging as one of the cornerstones of personalized medicine, from enabling discovery and development of novel treatments and diagnostics to facilitating collection, analysis and interpretation of data that ultimately helps an individual patient. SPECIAL REPORT PART 1: ‘Good enough’ is no longer good enough By Randall Willis, ddn Features Editor Aiming beyond the standard of care in oncology By Randall Willis, ddn Features Editor Are we really making things better for cancer patients? High-profile oncology partnership By Jim Cirigliano, ddn Contributing Editor Araxes Pharma and Janssen Biotech ink oncology drug development deal Natural neighbors By Kelsey Kaustinen, ddn Features Editor OSU, Biosortia link up to identify natural products for potential cancer treatments  |
 MSKCC, IBM partner on decision support system
03-22-2012
SHARING OPTIONS:
NEW YORK—A new partnership was announced this week, with the
Memorial Sloan-Kettering Cancer Center (MSKCC) and IBM announcing that they
would be collaborating to develop a powerful new tool based on IBM Watson to
provide medical professionals with better access to current cancer data and
practices. The decision support tool will aid in the creation of individualized
diagnostic and treatment regimens for patients with cancer.
The IBM Watson system, best known for besting human
contestants on Jeopardy, is capable of interpreting queries in natural language
and searches millions of pages in seconds with statistical analysis and
advanced analytics. Responses are evidence-based and statistically ranked, and
MSKCC’s oncologists will help to develop the system to synthesize patients’
medical information, treatment guidelines and published research. MSKCC offers
expansive clinical knowledge as well as molecular and genomic data and a large
repository of cancer case histories. The end result will be an outcome- and
evidence-based decision support system, one that can provide detailed
diagnostic and treatment options for individual patients based on up-to-date
research.
The partnership fits well into the growing trend of
personalized medicine, especially as more is discovered about the increasing
complexity of cancer and cancer fatalities continue to rise. The disease is now
the second most common cause of death in the United States next to heart
disease, and approximately 1.6 million new cases are expected to be diagnosed
this year in the United States alone, according to the American Cancer Society.
The companies have already begun working on the first applications for the new
system, which will include breast, lung and prostate cancers, and aim to start
piloting the solutions late this year, with wider distribution to take place
late in 2013.
“This comprehensive, evidence-based approach will profoundly
enhance cancer care by accelerating the dissemination of practice-changing
research at an unprecedented pace,” Dr. Mark G. Kris, Chief of Thoracic
Oncology Service at MSKCC, said in a press release. Kris is one of the
clinicians heading up development efforts for the new system.
SOURCE: MSKCC press release Code: E03221201 Back |
       |
||
|
 
 
|
 |
© Copyright 2013 Old River Publications LLC. All righs reserved. | Web site managed and designed by OffWhite.